
Presentation of the report
This report has been prepared in accordance with the Norwegian Transparency Act (the “Transparency Act”) section 5 and summarizes the policies and procedures in Nattopharma AS (“Nattopharma”) with respect to safeguarding of human rights and decent working conditions and provides information on the imolementation and results of NattoPharma’s due diligence.
View the 2023 Transparency Act Report
Latest news & videos

- MenaQ7®
- Mobility & Joint
- News
- May 21, 2025
K2SAC’s 4th Meeting Showcases New Clinical Insights and Emerging Talent in Vitamin K2 Research
On May 12-13, the 4th Gnosis Vitamin K2 Scientific Advisory Committee meeting convened leading...

- Adonat®
- Digestion & Gut
- Mobility & Joint
- May 13, 2025
Adonat® Premium SAMe: Your Go-To Brain-Health Solution Through Adulthood
A short, dynamic video dedicated to S-Adenosyl-Methionine benefits, part of a new educational series,...

- News
- Quatrefolic®
- Wellness & Immune
- May 12, 2025
The New Quatrefolic® Liquid Formulation Solution
The global market for liquid dietary supplements is experiencing steady growth, driven by increasing...